Medical Developments International Ltd (ASX: MVP) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Medical Developments International Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Medical Developments International Ltd (ASX: MVP)
Latest News
Share Gainers
These 4 small ASX shares are already up more than 19% in 2024!
Small Cap Shares
Buy these small cap ASX shares in September: Bell Potter
Earnings Results
Medical Developments share price leaps 5% on FY22 revenue boost
Share Fallers
Why Alliance, Aurizon, MVP, and Suncorp shares are dropping today
Share Fallers
Here's why the Medical Developments share price is sinking 17% on Monday
Healthcare Shares
Medical Developments share price halted amid 'significant near-term opportunities'
Share Gainers
Why Core Lithium, MVP, Rio Tinto, and South32 shares are rising today
Healthcare Shares
Why the Medical Developments International (ASX:MVP) share price is rocketing 32% higher
Earnings Results
Medical Developments International (ASX:MVP) share price on watch as losses widen
Healthcare Shares
Medical Developments (ASX:MVP) share price hits new 52 week low
Share Fallers
Medical Developments (ASX:MVP) share price falls on $13 million loss
Share Fallers
Why Buddy, Evolution, Medical Dev International, & Whitefield are dropping
Frequently Asked Questions
-
Yes, Medical Developments International historically pays two fully franked dividends a year.
-
Medical Developments International generally pays its dividends in April and October.
-
Medical Developments International Ltd listed on the ASX on 15 December 2003.
Dividend Payment History Data provided by Morningstar.
Ex-Date | Amount | Franking | Type | Payable |
---|---|---|---|---|
05 Mar 2020 | $0.0200 | 100.00% | Interim | 17 Apr 2020 |
03 Sep 2019 | $0.0200 | 100.00% | Final | 04 Oct 2019 |
07 Mar 2019 | $0.0200 | 100.00% | Interim | 17 Apr 2019 |
30 Aug 2018 | $0.0200 | 100.00% | Final | 05 Oct 2018 |
02 Mar 2018 | $0.0200 | 100.00% | Interim | 13 Apr 2018 |
31 Aug 2017 | $0.0000 | 100.00% | Final | 06 Oct 2017 |
03 Mar 2017 | $0.0200 | 100.00% | Interim | 10 Apr 2017 |
01 Sep 2016 | $0.0200 | 100.00% | Final | 07 Oct 2016 |
02 Mar 2016 | $0.0200 | 100.00% | Interim | 08 Apr 2016 |
02 Sep 2013 | $0.0200 | 100.00% | Final | 11 Oct 2013 |
27 Feb 2013 | $0.0300 | 100.00% | Interim | 11 Apr 2013 |
28 Feb 2012 | $0.0300 | 100.00% | Interim | 11 Apr 2012 |
31 Aug 2011 | $0.0300 | 100.00% | Final | 10 Oct 2011 |
MVP ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
---|---|---|---|---|---|
YesNo |
About Medical Developments International Ltd
Medical Developments International Ltd (ASX: MVP) is an Australian- based pharmaceutical company. It manufactures and distributes pharmaceutical drugs covering pain management, asthma, and resuscitation, as well as medical and veterinary equipment.
The company has three business units: pharmaceuticals, medical devices, and veterinary products. The majority of its revenue comes from its pharmaceuticals segment which produces and sells the pain relief drug Penthrox within Australia, New Zealand, and the United Kingdom, as well as some sales in other countries.
MVP Share Price History Data provided by Morningstar.
Date | Close | Change | % Change | Volume | Open | High | Low |
---|---|---|---|---|---|---|---|
23 Apr 2024 | $0.55 | $0.01 | 1.83% | 44,280 | $0.55 | $0.57 | $0.54 |
22 Apr 2024 | $0.55 | $-0.02 | -3.54% | 81,549 | $0.56 | $0.56 | $0.55 |
19 Apr 2024 | $0.57 | $0.02 | 3.67% | 34,927 | $0.55 | $0.57 | $0.54 |
18 Apr 2024 | $0.55 | $-0.01 | -1.82% | 52,219 | $0.56 | $0.57 | $0.55 |
17 Apr 2024 | $0.55 | $0.00 | 0.00% | 53,936 | $0.56 | $0.57 | $0.55 |
16 Apr 2024 | $0.55 | $-0.02 | -3.48% | 167,231 | $0.58 | $0.58 | $0.54 |
15 Apr 2024 | $0.58 | $-0.01 | -1.71% | 48,661 | $0.59 | $0.59 | $0.57 |
12 Apr 2024 | $0.59 | $-0.02 | -3.33% | 45,265 | $0.60 | $0.60 | $0.58 |
11 Apr 2024 | $0.60 | $-0.01 | -1.64% | 190,051 | $0.61 | $0.61 | $0.59 |
10 Apr 2024 | $0.61 | $-0.01 | -1.63% | 73,124 | $0.62 | $0.62 | $0.61 |
09 Apr 2024 | $0.62 | $0.01 | 1.65% | 42,061 | $0.60 | $0.62 | $0.59 |
08 Apr 2024 | $0.61 | $0.00 | 0.00% | 149,289 | $0.61 | $0.62 | $0.59 |
05 Apr 2024 | $0.61 | $-0.01 | -1.63% | 66,202 | $0.62 | $0.62 | $0.61 |
04 Apr 2024 | $0.62 | $0.00 | 0.00% | 145,921 | $0.61 | $0.62 | $0.61 |
03 Apr 2024 | $0.62 | $0.02 | 3.33% | 47,035 | $0.63 | $0.64 | $0.60 |
02 Apr 2024 | $0.60 | $0.00 | 0.00% | 118,372 | $0.59 | $0.61 | $0.58 |
28 Mar 2024 | $0.60 | $0.02 | 3.45% | 143,869 | $0.59 | $0.61 | $0.57 |
27 Mar 2024 | $0.58 | $-0.03 | -4.96% | 52,687 | $0.61 | $0.61 | $0.58 |
26 Mar 2024 | $0.61 | $0.01 | 1.68% | 50,303 | $0.60 | $0.61 | $0.60 |
Director Transactions Data provided by Morningstar.
Date | Director | Type | Amount | Value | Notes |
---|---|---|---|---|---|
03 Apr 2024 | Russell Basser | Buy | 15,873 | $9,761 |
On-market trade.
|
07 Sep 2023 | Gordon Naylor | Buy | 56,000 | $49,559 |
On-market trade.
|
Directors & Management Data provided by Morningstar.
Name | Title | Start Date | Profile |
---|---|---|---|
Mr Leon Hoare | Non-Executive Director | Sep 2013 |
Mr Hoare is the Managing Director of Lohmann & Rauscher, Australia & New Zealand (ANZ), a private EU based medical device company. Previously, he was Managing Director of Smith & Nephew ANZ (all divisions) until 2015, one of the Smith & Nephew's largest global subsidiaries outside the USA. He served as President of Smith & Nephew's Asia Pacific Advanced Wound Management (AWM) business for 5 years and was a member of the Global Executive Management for the AWM Division. In his 24 years with Smith & Nephew, he also held roles in Marketing, Divisional and General Management. His career has also included a senior role at Bristol Myers Squibb (medical devices), and as Vice Chair of the board of Australia's peak medical device industry body, Medical Technology Association of Australia. Mr Hoare is also the chair of the Human Resources Committee.
|
Mr Richard Betts | Non-Executive Director | May 2021 |
Mr Betts is an experienced executive who has held senior roles with ASX listed entities over 20 years. His previous roles with multiple listed companies has provided a deep understanding of working in various jurisdictions, including North America, Europe and Asia. Mr Betts has extensive financial and governance experience within international manufacturing environments. Mr Betts is Chair of the Audit and Risk Committee and a member of Continuous Disclosure Committee.
|
Ms Maria (Mary) Elisabeth Sontrop | Non-Executive Director | Mar 2021 |
Ms Sontrop has extensive international experience in the biopharmaceutical sector across manufacturing operations, quality, and business integration. During her 28 years with CSL Limited, Ms Sontrop was a part of CSL's globalisation through a series of major acquisitions. This included primary responsibility for the turnaround of unprofitable manufacturing operations. Subsequently as head of global plasma manufacturing, Ms Sontrop delivered a globally integrated manufacturing network spanning four countries. As head of CSL's Australia and New Zealand pharmaceutical business, Ms Sontrop and her team delivered Australia's most successful adolescent/adult immunisation program and achieved USFDA (US Food & Drug Administration) approval to manufacture and export CSL's seasonal and pandemic influenza vaccines. Ms Sontrop also has international governance experience. She is a member of Audit and Risk Committee.
|
Ms Christine Emmanuel-Donnelly | Non-Executive Director | May 2020 |
Ms Emmanuel-Donnelly is an experienced IP and business development professional having 35 years of experience locally and internationally. She was previously Vice President of the Institute of Patent & Trademarks Attorneys of Australia for over 2 years. She is a member of Audit and Risk Committee.
|
Mr Gordon Naylor | Non-Executive DirectorNon-Executive Chairman | Oct 2020 |
Mr Naylor has enjoyed a long and successful international business career. For over 30 years he was a key part of the internationalisation of CSL, holding a range of business and functional leadership roles including Chief Financial Officer. He is also a member of the Human Resources Committee and Continuous Disclosure
Committee. |
Dr Russell Basser | Non-Executive Director | Aug 2023 |
Dr Basser has 30 years of international medical and biopharmaceutical experience. Dr Bassers worked as a medical oncologist in Melbourne prior to joining CSL in 2001. During his 21 years at CSL, he held multiple global executive roles, including Head of Global Clinical Development, Chief Medical Officer and Senior VP of Research and Development for CSL Seqirus. Dr Basser has substantial expertise in international drug and vaccine development and spent several years based in the USA. Dr Basser currently serves as a non-executive director on the Boards of Starpharma Holdings Limited and Doherty Clinical Trials. He has previously served on the Board of the ANZ Breast Cancer Trials Group and the Hadassah Australia Medical Research Collaboration.
|
Mr Brent MacGregor | Chief Executive Officer | Nov 2020 |
-
|
Ms Tara Eaton | Company SecretaryGeneral Counsel | Aug 2022 |
-
|
Brent MacGregor | Chief Executive Officer |
-
|
|
Tara Eaton | Company SecretaryGeneral Counsel |
-
|
Top Shareholders Data provided by Morningstar.
Name | Shares | Capital |
---|---|---|
Hsbc Custody Nominees (Australia) Limited | 9,743,442 | 11.29% |
Lawn Views Pty Ltd <Angela Williams Family A/C> | 5,904,120 | 6.84% |
P Morgan Nominees Australia Pty Limited | 3,444,174 | 3.99% |
Moggs Creek Pty Ltd <Moggs Creek Super A/C> | 2,905,320 | 3.37% |
Netwealth Investments Limited <Wrap Services A/C> | 2,731,071 | 3.16% |
Citicorp Nominees Pty Limited | 1,726,027 | 2.00% |
Dr Russell Kay Hancock | 1,714,214 | 1.99% |
Kidder Peabody Pty Ltd | 1,042,945 | 1.21% |
Ubs Nominees Pty Ltd | 1,040,936 | 1.21% |
BNP Paribas Nominees Pty Ltd Acf Clearstream | 1,001,569 | 1.16% |
Mr David Williams <William Street A/C> | 861,817 | 1.00% |
Payne Media Pty Ltd | 860,147 | 1.00% |
Neweconomy Com Au Nominees Pty Limited <900 Account> | 762,881 | 0.88% |
Bnp Paribas Nominees Pty Ltd <Agency Lending Drp A/C> | 682,749 | 0.79% |
Naylor-Stewart Investments Pty Ltd <Naylor-Stewart Family A/C> | 645,167 | 0.75% |
Mr Alistair David Strong | 630,000 | 0.73% |
Mrs Virginia Catherine Hancock | 618,487 | 0.72% |
National Nominees Limited | 524,026 | 0.61% |
Bnp Paribas Nominees Pty Ltd Hub24 Custodial Serv Ltd <Drp A/C> | 502,548 | 0.58% |
Norman Chan Pty Ltd <Blue Elephant Family A/C> | 450,000 | 0.52% |